10-May-2024
U.S. dialysis volumes expected to rebound in 2024 despite GLP-1 impact
Seeking Alpha News (Sat, 11-May 12:13 PM ET)
DaVita Inc. to Participate in the BofA Securities 2024 Health Care Conference
PRNewswire (Thu, 9-May 6:15 PM ET)
DaVita Honors 54 Nephrology Nurses with DAISY Awards
PRNewswire (Thu, 9-May 10:00 AM ET)
DaVita Inc. 1st Quarter 2024 Results
PRNewswire (Thu, 2-May 4:05 PM ET)
Garry Menzel joins GHO Capital as Operating Partner
Globe Newswire (Tue, 23-Apr 7:45 AM ET)
DaVita's Global Operations Powered by 100% Renewable Energy
PRNewswire (Mon, 22-Apr 9:00 AM ET)
DaVita Inc. Schedules 1st Quarter 2024 Investor Conference Call
PRNewswire (Wed, 17-Apr 7:31 PM ET)
DaVita Announces Dennis Pullin to its Board of Directors
PRNewswire (Wed, 10-Apr 9:00 AM ET)
The American Diabetes Association and DaVita Strengthen Alliance to Tackle Chronic Disease Head-On
PRNewswire (Mon, 11-Mar 4:40 PM ET)
DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2024
PRNewswire (Fri, 8-Mar 5:21 PM ET)
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Davita trades on the NYSE stock market under the symbol DVA.
As of May 10, 2024, DVA stock price declined to $137.52 with 709,966 million shares trading.
DVA has a beta of 0.51, meaning it tends to be less sensitive to market movements. DVA has a correlation of 0.03 to the broad based SPY ETF.
DVA has a market cap of $12.06 billion. This is considered a Large Cap stock.
Last quarter Davita reported $3 billion in Revenue and $2.38 earnings per share. This beat revenue expectation by $41 million and exceeded earnings estimates by $.43.
In the last 3 years, DVA stock traded as high as $145.04 and as low as $65.28.
The top ETF exchange traded funds that DVA belongs to (by Net Assets): COWZ, VTI, VOO, VB, VBR.
DVA has outperformed the market in the last year with a price return of +38.5% while the SPY ETF gained +27.8%. DVA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +25.2% and +3.0%, respectively, while the SPY returned +4.2% and +2.5%, respectively.
DVA support price is $135.41 and resistance is $140.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DVA stock will trade within this expected range on the day.